Now Open: AHS Headache & Migraine Competitive Grant Program: Migraine & Women’s Health
The American Headache Society, in collaboration with Pfizer, is launching a new funding opportunity through the Headache & Migraine Competitive Grant Program: Migraine and Women’s Health. Grant funding is available for collaborative quality improvement and research projects focused on improving care for women, who are disproportionately affected by migraine. AHS is now inviting RFP submissions, with Letters of Intent due May 5, 2026.
Migraine remains one of the most prevalent and disabling neurological diseases, significantly affecting quality of life, productivity, and overall health, especially among women. Through this opportunity, AHS is seeking submissions for projects that improve care delivery, expand access, and drive measurable outcomes for patients. At the core, the goal is to support scalable, patient-centered solutions in migraine care.
Through this program, AHS and Pfizer continue their shared commitment to advancing headache medicine, supporting projects that lead to practical, scalable improvements in patient care.
Key Dates
- Request for Proposals posted: March 9, 2026
- Letter of Intent deadline: May 5, 2026
- Anticipated invitation to submit full proposal: June 30, 2026
- Invited full proposal deadline: August 28, 2026
- Anticipated award notification: October 30, 2026
- Anticipated project start date: December 1, 2026 or later
Funding Details
- Individual projects may request up to $200,000 USD total
- Project duration: up to two (2) years
- Proposals with smaller budgets are encouraged
Important: Only applicants with accepted Letters of Intent (LOIs), will be invited to submit a full proposal.
If you’re interested in applying, submit a two-page LOI by May 5, 2026. You can review the official RFP for full eligibility criteria, submission instructions, and additional details, or reach out to AHS headquarters with any questions.